OMEICOS Therapeutics develops a novel, first-in-class, small molecule drug addressing a new Mode of Action for the treatment and prevention of atrial fibrillation.


Dr. Robert Fischer


OMEICOS Therapeutics Raises EUR 6.2 Million in Series A to Advance Lead Candidate in Atrial Fibrillation

OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation (AF), today announced that it has raised EUR 6.2 million in a Series A round. Participating in the round were Vesalius…

OMEICOS Therapeutics: Novel therapy for the treatment of atrial fibrillation

Our heart beats 60 to 100 times per minute, around 42 million times per year. Disturbances of the heart’s rhythm – so called arrhythmia- occur frequently, in particular in older people. Atrial fibrillation, the most common type of arrhythmia, typically represents with irregular palpitations, often associated with…

Info & Contact

Robert Fischer


Robert-Rössle-Straße 10
13125 Berlin

In portfolio

17. Sep 2013